Scleroderma - Articles and news items

Orphan drug designation granted to Boehringer Ingelheim’s systemic sclerosis drug

Industry news / 13 September 2016 / Niamh Louise Marriott, Digital Content Producer

Senscis is specifically evaluating nintedanib to understand the disease process and potential benefit of the compound to treat SSc-ILD…

Cytori launches managed access programme for ECCS-50 for scleroderma

Industry news / 12 January 2016 / Victoria White

ECCS-50 is an autologous, adipose-derived cell therapy produced at the patient’s bedside and administered via a series of hand injections, in a single same-day procedure…

Biologics: Teamwork pays off in race to expand market for monoclonal antibodies

Biologics, Issue 5 2012 / 22 October 2012 / Bahija Jallal, Executive Vice President, Research & Development, MedImmune

The first biologic drug – infliximab (Remicade) – was launched in 1998 with initial sales of USD 500 million per annum. By 2010, Reuters’ top 10 drugs by sales included five biologics (Remicade, Enbrel, Humira, Avastin and Humira) generating around USD 34 billion in revenue, including USD 7.4 billion from Remicade1. Reuters have predicted that by 2014, these five will be joined in the top 10 by Herceptin, that their combined sales will be USD 47 billion per annum and that the three top-selling drugs in the world will be biologics. It is fair to say then that biologics are transforming the landscape of the pharmaceutical industry – but how and why have these complex molecules achieved this?

Bristol Myers Squibb logo

Bristol-Myers Squibb completes acquisition of Amira Pharmaceuticals

Industry news, News / 8 September 2011 / Bristol-Myers Squibb Company

Bristol-Myers Squibb Company has completed its previously announced acquisition of privately held Amira Pharmaceuticals, Inc…

Bristol Myers Squibb logo

Bristol-Myers Squibb to acquire Amira Pharmaceuticals

Industry news, News / 21 July 2011 / Bristol-Myers Squibb

Bristol-Myers Squibb will acquire privately held Amira Pharmaceuticals, a small-molecule pharmaceutical company…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...